A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis
Open Access
- 4 May 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (5), e0232394
- https://doi.org/10.1371/journal.pone.0232394
Abstract
Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis. 132 women with bacterial vaginosis were randomized 1:1:1:1 to Astodrimer 0.5% (N = 34), 1% (N = 33), or 3% (N = 32) Gel or hydroxyethyl cellulose placebo gel (N = 33) at a dose of 5 g vaginally once daily for 7 days at 6 centers in the United States. The primary endpoint was clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH ≥4.5; 2) ≥20% clue cells; or 3) positive whiff test) at study days 21–30. Secondary analyses included clinical cure at study days 9–12, patient-reported symptoms, acceptability and adverse events. The Astodrimer 1% Gel dose was superior to placebo for the primary and selected secondary efficacy measures in the modified intent-to-treat population. Clinical cure rates at day 9–12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P = .002], 74.1% [20/27; P < .001], and 55.2% [16/29; P = .001], respectively, vs. 22.2% [6/27]). At day 21–30, clinical cure rates were 46.2% (12/26) for the 1% dose vs. 11.5% for placebo (3/26; P = .006). A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9–12 and day 21–30 for Astodrimer Gel groups compared with placebo. Adverse events considered potentially treatment-related occurred in only 25% of Astodrimer Gel-treated patients vs. 22% of placebo patients. Astodrimer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis.Keywords
Funding Information
- Starpharma Pty Ltd
This publication has 30 references indexed in Scilit:
- A multicenter, double‐blind, randomized, placebo‐controlled study of rifaximin for the treatment of bacterial vaginosisInternational Journal of Gynecology & Obstetrics, 2012
- Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)AIDS, 2011
- Bacterial Vaginosis: Identifying Research Gaps Proceedings of a Workshop Sponsored by DHHS/NIH/NIAIDSexually Transmitted Diseases, 2010
- Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral ActivityPLOS ONE, 2010
- Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I StudySexually Transmitted Diseases, 2010
- A Randomized Trial of the Duration of Therapy with Metronidazole plus or minus Azithromycin for Treatment of Symptomatic Bacterial VaginosisClinical Infectious Diseases, 2007
- High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with RecurrenceThe Journal of Infectious Diseases, 2006
- Adherent Biofilms in Bacterial VaginosisObstetrics & Gynecology, 2005
- In Vitroandin VivoCharacterization of a Potential Universal Placebo Designed for Use in Vaginal Microbicide Clinical TrialsAIDS Research and Human Retroviruses, 2005
- Dendrimers as Drugs: Discovery and Preclinical and Clinical Development of Dendrimer-Based Microbicides for HIV and STI PreventionMolecular Pharmaceutics, 2005